Darolutamide Delays Prostate Cancer Progression in Men with Resistant Prostate Cancer

Results of the phase III ARAMIS clinical trial were published in The New England Journal of Medicine and demonstrated that Darolutamide plus androgen deprivation therapy ADT significantly extends metastasis-free survival compared to placebo plus ADT in no [...]